natgillin/translations-raw huggingface dataset:
In the light of the conclusions of the assessment report, it is appropriate to require that products containing aluminium phosphide and used as insecticides be authorised only for use by trained professionals in accordance with Article 10(2)(i)(e) of Directive 98/8/EC, and that specific risk mitigation measures are applied at product authorisation level to such products.
Glede na ugotovitve poročila o oceni je primerno zahtevati, da se v skladu s členom 10(2)(i)(e) Direktive 98/8/ES pri izdaji dovoljenj za pripravke, ki vsebujejo aluminijev fosfid in se uporabljajo kot insekticidi, uporaba dovoli samo usposobljenim strokovnjakom in da se uporabijo posebni ukrepi za zmanjšanje tveganja.
Such measures should be aimed at limiting the risk of exposure of users to aluminium phosphide to an acceptable level.
Ti ukrepi morajo biti usmerjeni k omejitvi tveganja izpostavljenosti uporabnikov aluminijevemu fosfidu na sprejemljivo raven.
Regulation (EC) No 396/2005 of the European Parliament and of the Council of 23 February 2005 on maximum residue levels of pesticides in or on food and feed of plant and animal origin and amending Council Directive 91/414/EEC [4] establishes maximum limits for aluminium phosphide residues which are present in or on food and feed.
Uredba Evropskega parlamenta in Sveta (ES) št. 396/2005 z dne 23. februarja 2005 o mejnih vrednostih ostankov pesticidov v ali na hrani in krmi rastlinskega in živalskega izvora ter o spremembi Direktive Sveta 91/414/EGS [4] določa mejne vrednosti ostankov aluminijevega fosfida, ki so prisotni v ali na hrani in krmi.
Pursuant to Article 3(2)(c) of Regulation (EC) No 396/2005, the maximum residue limits apply to any pesticide residues, including those which may arise as a result of use as a biocide.
Na podlagi člena 3(2)(c) Uredbe (ES) št. 396/2005 se mejne vrednosti ostankov uporabljajo za vse ostanke pesticidov, vključno s tistimi, ki lahko nastanejo kot posledica njihove uporabe kot biocidov.
Member States should ensure that adequate residue trials are provided at product authorisation to allow consumer risk assessment.
Države članice morajo ob izdaji dovoljenj za pripravke zagotoviti ustrezne preskuse za ugotavljanje ostankov, da bi se lahko ocenilo tveganje za potrošnike.
Furthermore, labels and/or safety data sheets for authorised products must contain instructions for use, such as the adherence to waiting periods, which ensure compliance with the provisions laid down in Article 18 of Regulation (EC) No 396/2005.
Nadalje morajo oznake in/ali varnostni listi dovoljenih pripravkov vsebovati navodila za uporabo, določena v členu 18 Uredbe (ES) št. 396/2005.
After inclusion, Member States should be allowed a reasonable period to implement Article 16(3) of Directive 98/8/EC, and in particular, to grant, modify or cancel authorisations of biocidal products in product-type 18 containing aluminium phosphide to ensure that they comply with Directive 98/8/EC.
Državam članicam je treba po vključitvi zagotoviti ustrezno obdobje za izvedbo člena 16(3) Direktive 98/8/ES in zlasti za izdajo, spremembo ali razveljavitev dovoljenj za biocidne pripravke v 18. vrsti izdelkov, ki vsebujejo aluminijev fosfid, da se zagotovi njihova skladnost z Direktivo 98/8/ES.
They shall apply those provisions from 1 February 2012.
Uporabljajo se od 1. februarja 2012.
The following is added to entry ‘No 20’ in Annex I to Directive 98/8/EC:
V Prilogo I k Direktivi 98/8/ES se vstavi naslednji vnos „št. 20“:
For products containing aluminium phosphide that may lead to residues in food or feed, labels and/or safety data sheets for authorised products must contain instructions for use, such as the adherence to waiting periods, which ensure compliance with the provisions laid down in Article 18 of Regulation (EC) No 396/2005 of the European Parliament and of the Council (OJ L 70, 16.3.2005, p. 1).’
Za pripravke, ki vsebujejo aluminijev fosfid in lahko puščajo ostanke v živilih ali krmi, morajo oznake in/ali varnostni listi dovoljenih pripravkov vsebovati navodila za uporabo, kot je upoštevanje čakalne dobe, kar zagotavlja skladnosti z določbami člena 18 Uredbe (ES) št. 396/2005 Evropskega parlamenta in Sveta (UL L 70, 16.3.2005, str. 1.).“
For the implementation of the common principles of Annex VI, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm
Za izvajanje splošnih načel Priloge VI so vsebina in sklepne ugotovitve poročil o oceni na voljo na spletnih straneh Komisije: http://ec.europa.eu/comm/environment/biocides/index.htm
Commission Directive 2010/10/EU
Direktiva Komisije 2010/10/EU
amending Directive 98/8/EC of the European Parliament and of the Council to include brodifacoum as an active substance in Annex I thereto
o spremembi Direktive 98/8/ES Evropskega parlamenta in Sveta za vključitev brodifakuma kot aktivne snovi v Prilogo I k Direktivi
That list includes brodifacoum.
Navedeni seznam vključuje brodifakum.
Pursuant to Regulation (EC) No 1451/2007, brodifacoum has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product-type 14, rodenticides, as defined in Annex V to Directive 98/8/EC.
Na podlagi Uredbe (ES) št. 1451/2007 je bila v skladu s členom 11(2) Direktive 98/8/ES opravljena presoja brodifakuma glede uporabe v 14. vrsti izdelkov, rodenticidih, kot so opredeljeni v Prilogi V k Direktivi 98/8/ES.
Italy was designated as Rapporteur Member State and submitted the competent authority report, together with a recommendation, to the Commission on 5 June 2005 in accordance with Article 14(4) and (6) of Regulation (EC) No 1451/2007.
Italija, ki je bila imenovana za državo članico poročevalko, je 5. junija 2005 v skladu s členom 14(4) in (6) Uredbe (ES) št. 1451/2007 Komisiji poslala poročilo pristojnega organa in priporočilo.
In accordance with Article 15(4) of Regulation (EC) No 1451/2007, the findings of the review were incorporated, within the Standing Committee on Biocidal Products on 17 September 2009, in an assessment report.
V skladu s členom 15(4) Uredbe (ES) št. 1451/2007 so bile ugotovitve pregleda v Stalnem odboru za biocidne pripravke 17. septembra 2009 vključene v poročilo o oceni.
It appears from the examinations made that biocidal products used as rodenticides and containing brodifacoum may be expected not to present a risk to humans except for accidental incidents with children.
Preiskave so pokazale, da je za biocidne pripravke, ki se uporabljajo kot rodenticidi in vsebujejo brodifakum, mogoče pričakovati, da za ljudi ne pomenijo tveganja, razen pri naključnih incidentih z otroki.
A risk has been identified regarding non-target animals and the environment.
Ugotovljeno je bilo tveganje za neciljne živali in okolje.
Moreover, it has not yet been established that adequate alternatives to brodifacoum exist, which are both equally effective and less damaging to the environment.
Poleg tega še ni bilo ugotovljeno, ali za brodifakum obstajajo ustrezne nadomestne snovi, ki bi bile enako učinkovite in okolju manj škodljive.
It is therefore justified to include brodifacoum in Annex I for a limited period, in order to ensure that in all Member States authorisations for biocidal products used as rodenticides and containing brodifacoum can be granted, modified, or cancelled in accordance with Article 16(3) of Directive 98/8/EC.
Zato je upravičeno vključiti brodifakum v Prilogo I za omejeno obdobje, da se v vseh državah članicah v skladu s členom 16(3) Direktive 98/8/ES zagotovi, da se lahko izdajo, spremenijo ali razveljavijo dovoljenja za biocidne pripravke, ki se uporabljajo kot rodenticidi in vsebujejo brodifakum.
In the light of the findings of the assessment report, it is appropriate to require that specific risk mitigation measures are applied at product authorisation level to products containing brodifacoum and used as rodenticides.
Glede na ugotovitve poročila o oceni je primerno zahtevati, da se na ravni izdaje dovoljenja za pripravke, ki vsebujejo brodifakum in se uporabljajo kot rodenticidi, uporabijo posebni ukrepi za zmanjšanje tveganja.
To this end, certain constraints such as the maximum concentration, the prohibition on marketing the active substance in products used as tracking powder or in products which are not ready for use, and the use of aversive agents should be imposed across the board, while other conditions should be imposed by the Member States on a case by case basis.
Zato je treba uvesti nekatere splošne omejitve, kot na primer največjo koncentracijo, prepoved trženja aktivne snovi v pripravkih, ki se uporabljajo kot sredstvo za posipanje, ali v pripravkih, ki jih ni mogoče takoj uporabiti, in uporabo averzivnih sredstev, druge pogoje pa bi morale za vsak primer posebej uvesti države članice.
Because of the identified risks and its characteristics, which render it potentially persistent, liable to bioaccumulate and toxic, or very persistent and very liable to bioaccumulate, brodifacoum should be included in Annex I for five years only and should be made subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in Annex I is renewed.
Zaradi ugotovljenih tveganj in lastnosti brodifakuma, ki je potencialno obstojen, se lahko kopiči v organizmih in je strupen ali je zelo obstojen in se zelo lahko kopiči v organizmih, ga je treba vključiti v Prilogo I samo za pet let, potem pa ga je mogoče ponovno vključiti vanjo le, če se v skladu z drugim pododstavkom člena 10(5)(i) Direktive 98/8/ES zanj izvede primerjalna ocena tveganja.
It is important that the provisions of this Directive be applied simultaneously in all the Member States in order to ensure equal treatment of biocidal products on the market containing the active substance brodifacoum and also to facilitate the proper operation of the biocidal products market in general.
Pomembno je, da se določbe te direktive uporabljajo hkrati v vseh državah članicah, tako da se zagotovi enako ravnanje z biocidnimi pripravki na trgu, ki vsebujejo aktivno snov brodifakum, in da se omogoči ustrezno delovanje trga biocidnih pripravkov nasploh.
After inclusion, Member States should be allowed a reasonable period to implement Article 16(3) of Directive 98/8/EC, and in particular, to grant, modify or cancel authorisations of biocidal products in product-type 14 containing brodifacoum to ensure that they comply with Directive 98/8/EC.
Državam članicam je treba po vključitvi zagotoviti ustrezno obdobje za izvedbo člena 16(3) Direktive 98/8/ES in zlasti za izdajo, spremembo ali razveljavitev dovoljenj za biocidne pripravke v 14. vrsti izdelkov, ki vsebujejo brodifakum, da se zagotovi njihova skladnost z Direktivo 98/8/ES.
Member States shall adopt and publish, by 31 January 2011 at the latest, the laws, regulations and administrative provisions necessary to comply with this Directive.
Države članice sprejmejo in objavijo zakone in druge predpise, potrebne za uskladitev s to direktivo, najpozneje 31. januarja 2011.
They shall apply those provisions from 1 February 2012.
Navedene predpise uporabljajo od 1. februarja 2012 dalje.
The following entry for the substance brodifacoum is inserted in Annex I to Directive 98/8/EC:
V Prilogo I k Direktivi 98/8/ES se vstavi naslednji vnos za snov brodifakum:
3-[3-(4'-bromobiphenyl-4-yl)-1,2,3,4-tetrahydro-1-napthyl]-4-hydroxycoumarin
3-[3-(4'-bromobifenil-4-il)-1,2,3,4-tetrahidro-1-naftil]-4-hidroksikumarin
EC No: 259-980-5
Št. ES: 259-980-5
CAS No: 56073-10-0
Št. CAS: 56073-10-0
In view of the fact that the active substance characteristics render it potentially persistent, liable to bioaccumulate and toxic, or very persistent and very liable to bioaccumulate, the active substance is to be subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in this Annex is renewed.
Zaradi lastnosti aktivne snovi, ki je potencialno obstojna, se lahko kopiči v organizmih in je strupena ali je zelo obstojna in se zelo lahko kopiči v organizmih, je treba zanjo pred njeno ponovno vključitvijo v to prilogo izvesti primerjalno oceno tveganja v skladu z drugim pododstavkom člena 10(5)(i) Direktive 98/8/ES.
The nominal concentration of the active substance in the products shall not exceed 50 mg/kg and only ready-for-use products shall be authorised.
Nazivna koncentracija aktivne snovi v pripravkih ne presega 50 mg/kg, dovoljenje pa se izda samo za pripravke, ki se lahko takoj uporabijo.
These include, amongst others, the restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait boxes.’
Ti med drugim vključujejo omejitev uporabe pripravka na zgolj poklicno, določitev največje velikosti embalaže ter določitev zahtev za uporabo vab, zaščitenih pred nepooblaščenimi posegi.“
Commission Directive 2010/11/EU
Direktiva Komisije 2010/11/EU
amending Directive 98/8/EC of the European Parliament and of the Council to include warfarin as an active substance in Annex I thereto
o spremembi Direktive 98/8/ES Evropskega parlamenta in Sveta za vključitev varfarina kot aktivne snovi v Prilogo I k Direktivi
That list includes warfarin.
Navedeni seznam vključuje varfarin.
Pursuant to Regulation (EC) No 1451/2007, warfarin has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product-type 14, rodenticides, as defined in Annex V to Directive 98/8/EC.
Na podlagi Uredbe (ES) št. 1451/2007 je bila v skladu s členom 11(2) Direktive 98/8/ES opravljena presoja varfarina glede uporabe v 14. vrsti izdelkov, rodenticidih, kot so opredeljeni v Prilogi V k Direktivi 98/8/ES.
Ireland was designated as Rapporteur Member State and submitted its report, together with a recommendation, to the Commission on 3 October 2005 in accordance with Article 14(4) and 14(6) of Regulation (EC) No 1451/2007.
Irska, ki je bila imenovana za državo članico poročevalko, je 3. oktobra 2005 v skladu s členom 14(4) in (6) Uredbe (ES) št. 1451/2007 Komisiji poslala poročilo in priporočilo.
It appears from the examinations made that biocidal products used as rodenticides and containing warfarin may be expected not to present a risk to humans except for accidental incidents with children.
Preiskave so pokazale, da je za biocidne pripravke, ki se uporabljajo kot rodenticidi in vsebujejo varfarin, mogoče pričakovati, da za ljudi ne pomenijo tveganja, razen pri naključnih incidentih z otroki.
However, warfarin is for the time being considered essential for reasons of public health and hygiene.
Trenutno zaradi javnega zdravja in higiene varfarin velja za nujnega.
It is therefore appropriate to include warfarin in Annex I, in order to ensure that in all Member States authorisations for biocidal products used as rodenticides and containing warfarin can be granted, modified, or cancelled in accordance with Article 16(3) of Directive 98/8/EC.
Zato je primerno vključiti varfarin v Prilogo I, da se v vseh državah članicah v skladu s členom 16(3) Direktive 98/8/ES zagotovi, da se izdajo, spremenijo ali razveljavijo dovoljenja za biocidne pripravke, ki se uporabljajo kot rodenticidi in vsebujejo varfarin.
In the light of the findings of the assessment report, it is appropriate to require that specific risk mitigation measures are applied at product authorisation level to products containing warfarin and used as rodenticides.
Glede na ugotovitve poročila o oceni je primerno zahtevati, da se pri izdaji dovoljenj za pripravek, ki vsebuje varfarin in se uporablja kot rodenticid, uporabijo posebni ukrepi za zmanjšanje tveganja.
To this end, certain constraints such as the maximum concentration, the prohibition on marketing the active substance in products which are not ready to use and the use of aversive agents should be imposed for all rodenticides containing warfarin, while other conditions should be imposed by the Member States on a case by case basis.
Zato je treba za vse rodenticide, ki vsebujejo varfarin, uvesti nekatere omejitve, kot na primer največjo koncentracijo, prepoved trženja aktivne snovi v pripravkih, ki niso že pripravljeni za uporabo, in uporabo averzivnih sredstev, druge pogoje pa bi morale za vsak primer posebej uvesti države članice.
In view of the identified risks, warfarin should be included in Annex I for five years only and should be made subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in Annex I is renewed.
Zaradi ugotovljenih tveganj je treba varfarin vključiti v Prilogo I samo za pet let, pred njegovo ponovno vključitvijo pa je treba v skladu z drugim pododstavkom člena 10(5)(i) Direktive 98/8/ES izvesti primerljivo oceno tveganja.
It is important that the provisions of this Directive be applied simultaneously in all the Member States in order to ensure equal treatment of biocidal products on the market containing the active substance warfarin and to facilitate the proper operation of the biocidal products market in general.
Pomembno je, da se določbe te direktive uporabljajo hkrati v vseh državah članicah, da se zagotovi enako ravnanje z biocidnimi pripravki na trgu, ki vsebujejo aktivno snov varfarin, in da se omogoči ustrezno delovanje trga biocidnih pripravkov na splošno.
After inclusion, Member States should be allowed a reasonable period to implement Article 16(3) of Directive 98/8/EC, and in particular, to grant, modify or cancel authorisations of biocidal products in product-type 14 containing warfarin to ensure that they comply with Directive 98/8/EC.
Državam članicam je treba po vključitvi zagotoviti ustrezno obdobje za izvedbo člena 16(3) Direktive 98/8/ES in zlasti za izdajo, spremembo ali razveljavitev dovoljenj za biocidne pripravke v 14. vrsti izdelkov, ki vsebujejo varfarin, da se zagotovi njihova skladnost z Direktivo 98/8/ES.
The following entry for the substance warfarin is added in Annex I to Directive 98/8/EC:
V Prilogi I k Direktivi 98/8/ES se doda snov varfarin:
(RS)-4-hydroxy-3-(3-oxo-1-phenylbutyl)coumarin
(RS)-4-hidroksi-3-(3-okso-1-funilbutil)kumarin
EC No: 201-377-6
Št. ES: 201-377-6
CAS No: 81-81-2
Št. CAS: 81-81-2
These include, amongst others, the possibility of restriction to professional use only, setting an upper limit to the package size and laying down obligations to use tamper resistant and secured bait boxes.’
Ti med drugim vključujejo omejitev pripravka za poklicno rabo, določitev največje velikosti embalaže ter določitev zahtev za uporabo vab, zaščitenih pred nepooblaščenimi posegi.“
Council Directive 2010/12/EU
Direktiva Sveta 2010/12/EU
amending Directives 92/79/EEC, 92/80/EEC and 95/59/EC on the structure and rates of excise duty applied on manufactured tobacco and Directive 2008/118/EC
o spremembi direktiv 92/79/EGS, 92/80/EGS in 95/59/ES glede strukture in stopnje trošarine, ki velja za predelani tobak, ter Direktive 2008/118/ES
In accordance with Article 4 of Council Directive 92/79/EEC of 19 October 1992 on the approximation of taxes on cigarettes [3] and Article 4 of Council Directive 92/80/EEC of 19 October 1992 on the approximation of taxes on manufactured tobacco other than cigarettes [4], an in-depth review has been carried out of the rates and structure of excise duties on tobacco products.
V skladu s členom 4 Direktive Sveta 92/79/EGS z dne 19. oktobra 1992 o približevanju davkov na cigarete [3] in členom 4 Direktive Sveta 92/80/EGS z dne 19. oktobra 1992 o približevanju davkov na predelani tobak razen cigaret [4] je bil opravljen poglobljen pregled stopenj in strukture trošarin za tobačne izdelke.
That review included provisions of Council Directive 95/59/EC of 27 November 1995 on taxes other than turnover taxes which affect the consumption of manufactured tobacco [5].
Ta pregled je vključeval določbe Direktive Sveta 95/59/ES z dne 27. novembra 1995 o davkih, razen prometnih davkov, ki vplivajo na porabo tobačnih izdelkov [5].
In order to ensure the proper functioning of the internal market and, at the same time, a high level of health protection, as required by Article 168 of the Treaty, bearing in mind that serious harm to health can be caused by tobacco products and that the Union is Party to the World Health Organization’s Framework Convention on Tobacco Control (FCTC), various changes should be made to the Union’s fiscal legislation on tobacco products.
Za zagotovitev pravilnega delovanja notranjega trga in hkrati visoke ravni varovanja zdravja, kakor zahteva člen 168 Pogodbe, in ob upoštevanju, da lahko tobačni izdelki resno škodujejo zdravju in da je Unija pogodbenica Okvirne konvencije SZO o nadzoru tobaka (FCTC), bi bilo treba na področju davčne zakonodaje Unije o tobačnih izdelkih uvesti različne spremembe.
These changes should take account of the situation prevailing for each of the various tobacco products.
Te spremembe bi morale upoštevati prevladujoče obstoječe stanje za vsakega od različnih tobačnih izdelkov.
As regards cigarettes, the arrangements should be simplified so as to create neutral conditions of competition for manufacturers, to reduce the partitioning of the tobacco markets and to underscore health objectives.
Glede cigaret bi bilo treba ureditev poenostaviti, da bi vzpostavili nevtralne konkurenčne pogoje za proizvajalce, zmanjšali delitev trgov tobaka in pripomogli k uresničevanju ciljev na področju zdravja.
To this end, the concept of the most popular price category should be replaced; the price related minimum requirement should refer to the weighted average retail selling price, whereas the monetary minimum should be applicable to all cigarettes.
V ta namen bi bilo treba nadomestiti koncept najbolje prodajane cenovne kategorije; s ceno povezana najnižja zahteva bi se morala nanašati na ponderirano povprečno maloprodajno ceno, medtem ko bi se moral najnižji denarni znesek uporabljati za vse cigarete.
For the same reasons, the weighted average retail selling price should also serve as a reference for measuring the importance of specific excise duty within the total tax burden.
Iz istih razlogov bi morala ponderirana povprečna maloprodajna cena prav tako služiti kot osnova za merjenje pomena specifične trošarine znotraj celotne davčne obremenitve.
Without prejudice to the mixed tax structure and the maximum percentage of the specific component on the total tax burden, Member States should be given more effective means to levy specific or minimum excise duty on cigarettes, so as to ensure that at least a certain minimum amount of taxation applies throughout the Union.
Brez poseganja v mešano davčno strukturo in najvišji možni delež specifičnega delnega zneska na celotno davčno obremenitev bi morale imeti države članice na voljo učinkovitejša sredstva za zaračunavanje specifične ali minimalne trošarine za cigarete, da bi na ta način zagotovili, da bi se v Uniji uporabljal vsaj določen najnižji znesek obdavčitve.
As regards fine-cut tobacco intended for the rolling of cigarettes, the Union price related minimum requirement should be expressed in such a way as to obtain effects similar to those in the field of cigarettes and should take the weighted average retail selling price as the point of reference.
Kar zadeva drobno rezani tobak za zvijanje cigaret, bi bilo treba s ceno povezane najnižje zahteve Unije izraziti tako, da bi bili njihovi učinki podobni tistim v zvezi s cigaretami, in za izhodišče vzeti njihovo ponderirano povprečno maloprodajno ceno.
The changes of prices and excise levels have been analysed, in particular, for cigarettes — by far the most important category of tobacco products — as well as for fine-cut tobacco intended for the rolling of cigarettes.
Analizirane so bile spremembe cen in stopnje trošarin, zlasti za cigarete kot zdaleč najbolj pomembno skupino tobačnih izdelkov, kakor tudi za drobno rezani tobak, namenjen za zvijanje cigaret.
The analysis shows that there are still considerable differences between Member States which may disturb the operation of the internal market.
Analiza kaže, da so med državami članicami še vedno znatne razlike, ki lahko motijo delovanje notranjega trga.